Lilly's EBGLYSS hits primary endpoint in Phase 3b trial

Eli Lilly announced on September 30, 2026, that EBGLYSS monotherapy met its primary and secondary endpoints at Week 16 in the Phase 3b ADtouch trial. The study evaluated adults and adolescents with moderate-to-severe hand and foot atopic dermatitis who had an inadequate response to topical treatments.

In the 221-patient trial, more than half of participants treated with EBGLYSS achieved clear or almost clear skin on their hands and feet by Week 16, with significant clearance emerging as early as Week 4. Patients treated with the drug also saw significant itch reduction starting at Week 2 and meaningful pain improvement at Week 1, with nearly three times as many patients achieving meaningful pain relief compared to placebo. Nearly eight out of 10 patients reported being satisfied or very satisfied with hand clearance at Week 16.

Treatment-emergent adverse events were reported in 41.8% of patients on EBGLYSS and 39.6% on placebo, with all cases deemed mild or moderate. The most common adverse reactions occurring in 5% or more of patients were nasopharyngitis and upper respiratory tract infections. Discontinuation rates due to adverse events stood at 0.9% for EBGLYSS and 2.7% for placebo.

Lilly holds the commercialization rights for EBGLYSS outside Europe, while Almirall licenses European rights. Lilly confirmed it has submitted the ADtouch data to the US Food and Drug Administration and plans additional global regulatory filings to update the drug's label.